Pay in 4 interest-free payments of $6.15 Learn more
Ships within 48 hours · Estimated delivery Aug 22 - Aug 27
Head to Henry Meds and select a treatment
Mounjaro (Tirzepatide) Dual action: targets both GLP-1 and GIP receptors Strong appetite suppression & improved blood sugar control Clinical trials show average body weight loss up to 22.5% over 72 weeks Wegovy (Semaglutide) Targets GLP-1 receptors only Licensed in the UK for obesity and cardiovascular protection STEP trials show 1521% body weight loss A new 7.2mg dose is expected in late 2025, with results potentially matching Mounjaro Both treatments are once-weekly injections, prescribed alongside healthy diet and lifestyle changes
However, if you feel persistently dizzy, faint, or unusually weak during GLP-1 therapy, notify your healthcare provider immediately
Additional common ingredients included phenoxyethanol (67.2%), tocopherol (65.7%), and sorbic acid derivatives (56.1%)
No oversized syringe needed
